What is Ultragenyx Pharmaceutical Inc. Annual Revenue?

Ultragenyx Pharmaceutical Inc. Annual Revenue rose 29.01%, in the last year to $560.23 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

What is Ultragenyx Pharmaceutical Inc. Annual Net Profit?

Ultragenyx Pharmaceutical Inc. Annual Net Profit rose 6.17% in the last year to $569.18 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

What is Ultragenyx Pharmaceutical Inc. Price to Earning Ratio?

Ultragenyx Pharmaceutical Inc. Price to Earning Ratio is -6.32, which is negative.

What is Ultragenyx Pharmaceutical Inc. Stock Price?

Ultragenyx Pharmaceutical Inc. Stock Price fell 17.96% and underperformed its sector by 26.85% in the past year.

What is Ultragenyx Pharmaceutical Inc. Quarterly Revenue?

Ultragenyx Pharmaceutical Inc. Quarterly Revenue rose 29.42% YoY to $164.88 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

What is Ultragenyx Pharmaceutical Inc. Quarterly Net profit?

Ultragenyx Pharmaceutical Inc. Quarterly Net profit fell 8.28% YoY to $133.38 M. Its sector's average net profit growth YoY for the quarter was -47.5%.

What is Ultragenyx Pharmaceutical Inc. Debt to Equity Ratio?

Ultragenyx Pharmaceutical Inc. Debt to Equity Ratio of 0.16 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Ultragenyx Pharmaceutical Inc. Return on Equity(ROE)?

Ultragenyx Pharmaceutical Inc. Return on Equity(ROE) for the last financial year was -214.5%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Ultragenyx Pharmaceutical Inc. Mutual Fund Holding?

Ultragenyx Pharmaceutical Inc. Mutual Fund Holding decreased by 0.28% in the last quarter to 64.39.

What is Ultragenyx Pharmaceutical Inc. Promoter Share Holding?

Ultragenyx Pharmaceutical Inc. Promoter Share Holding increased by 0.39% in the most recent quarter to 2.88%.

What is Ultragenyx Pharmaceutical Inc. Interest Coverage Ratio?

Ultragenyx Pharmaceutical Inc. Interest Coverage Ratio is -8, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Ultragenyx Pharmaceutical Inc. Institutional Holding?

Ultragenyx Pharmaceutical Inc. Institutional Holding remained the same in the last quarter at 94.43%.

How is the Ultragenyx Pharmaceutical Inc. today?

The Ultragenyx Pharmaceutical Inc. today is trading in the down by -1.97% at 38.86.

How has Ultragenyx Pharmaceutical Inc. performed historically?

The Ultragenyx Pharmaceutical Inc. is currently trading down -1.97% on an intraday basis in the past week the index rose 3.63%. The index has been down -13.55% in the past quarter and fell -17.96% in the past year. You can view this in the overview section.

Ultragenyx Pharmaceutical Inc. XNAS: RARE

Ultragenyx Pharmaceutical Inc. Live Share Price Today, Share Analysis and Chart

Name: Ultragenyx Pharmaceutical Inc.: Is Infosys Ltd. worth buying?
Item: Ultragenyx Pharmaceutical Inc.
Rating: 1.0444305
Author: Trendlyne DVM scores

Weak Stock

Download real time

38.86 -0.78 (-1.97%)

Near 52W Low of $37.02

423.2K XNAS Volume

XNAS 18 Mar, 2025 5:30 PM (EDT)

Ultragenyx Pharmaceutical ... Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	3,594.6
PE TTM Negative PE TTM Unavailable in chosen country	-6.3
PEG TTM Negative PEG TTM Unavailable in chosen country	-1
Price to Book High in industry Unavailable in chosen country	14.1
Institutional holding current Qtr % High in industry Unavailable in chosen country	94.4
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	29.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	29
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-8.3
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	6.2
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-74.2
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-95.7
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-18.9
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-214.5
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-38

All financials are in USD Million and price data in USD

Low Financial Strength

22.2 / 100

Expensive Valuation

9.0 / 100

Technically Bearish

30.1 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 130%

19 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Ultragenyx Pharmaceutical ... Stock Price Analysis

Day Price Range -2.0% 1 Day return Unavailable in chosen country	38.9 (LTP) 38.639.5 LowHigh
Week Price Range 3.6% 1 Week return Unavailable in chosen country	38.9 (LTP) 37.340.5 LowHigh
Month Price Range -8.5% 1 Month return Unavailable in chosen country	38.9 (LTP) 37.145 LowHigh
52 Week Price Range -18.0% 1 Year return Unavailable in chosen country	38.9 (LTP) 3760.4 LowHigh

View full Share Price History

Ultragenyx Pharmaceutical ... Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Ultragenyx Pharmaceutical Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-6.3

Avg. Estimate

-5.4

Low Estimate

-6.4

High Estimate

-3.7

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 14.6% in FY25

Consensus Recommendation

19 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 19 analysts for Ultragenyx Pharmaceutical Inc. is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Ultragenyx Pharmaceutical ... Stock Analysis

Ultragenyx Pharmaceutical ... stock analysis with key metrics, changes, and trends.

Ultragenyx Pharmaceutical ... Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$560.23 M	29.01%	positive	Annual Revenue rose 29.01%, in the last year to $560.23 M. Its sector's average revenue growth for the last fiscal year was 7.47%.
Annual Net Profit	$569.18 M	6.17%	positive	Annual Net Profit rose 6.17% in the last year to $569.18 M. Its sector's average net profit growth for the last fiscal year was -32.45%.
Price to Earning Ratio	-6.32	-	negative	Price to Earning Ratio is -6.32, which is negative.
Stock Price	$38.86	-17.96%	negative	Stock Price fell 17.96% and underperformed its sector by 26.85% in the past year.
Quarterly Revenue	$164.88 M	29.42%	positive	Quarterly Revenue rose 29.42% YoY to $164.88 M. Its sector's average revenue growth YoY for the quarter was 5.97%.
Quarterly Net profit	$133.38 M	8.28%	negative	Quarterly Net profit fell 8.28% YoY to $133.38 M. Its sector's average net profit growth YoY for the quarter was -47.5%.
Debt to Equity Ratio	0.16	-	positive	Debt to Equity Ratio of 0.16 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-214.50 %	-214.5%	negative	Return on Equity(ROE) for the last financial year was -214.5%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	64.39 %	-0.28%	negative	Mutual Fund Holding decreased by 0.28% in the last quarter to 64.39.
Promoter Share Holding	2.88 %	0.39%	positive	Promoter Share Holding increased by 0.39% in the most recent quarter to 2.88%.
Interest Coverage Ratio	-8	-	negative	Interest Coverage Ratio is -8, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	94.43 %	0%	neutral	Institutional Holding remained the same in the last quarter at 94.43%.

VIEW LESS

Loading data..

Ultragenyx Pharmaceutical Inc. - Company Profile

What does Ultragenyx Pharmaceutical Inc. do?

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Gross Remuneration

2024

Gross Remuneration

Year

Ultragenyx Pharmaceutical Inc. Live Share Price Today, Share Analysis and Chart

Near 52W Low of $37.02

Ultragenyx Pharmaceutical ... Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Ultragenyx Pharmaceutical ... Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Ultragenyx Pharmaceutical ... Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Ultragenyx Pharmaceutical Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 14.6% in FY25

Consensus Recommendation

The consensus recommendation from 19 analysts for Ultragenyx Pharmaceutical Inc. is STRONG BUY

Ultragenyx Pharmaceutical ... Stock Analysis

Ultragenyx Pharmaceutical ... stock analysis with key metrics, changes, and trends.

Annual Revenue rose 29.01%, in the last year to $560.23 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit rose 6.17% in the last year to $569.18 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

Price to Earning Ratio is -6.32, which is negative.

Stock Price fell 17.96% and underperformed its sector by 26.85% in the past year.

Quarterly Revenue rose 29.42% YoY to $164.88 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

Quarterly Net profit fell 8.28% YoY to $133.38 M. Its sector's average net profit growth YoY for the quarter was -47.5%.

Debt to Equity Ratio of 0.16 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -214.5%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.28% in the last quarter to 64.39.

Promoter Share Holding increased by 0.39% in the most recent quarter to 2.88%.

Interest Coverage Ratio is -8, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding remained the same in the last quarter at 94.43%.

Ultragenyx Pharmaceutical Inc. - Company Profile

What does Ultragenyx Pharmaceutical Inc. do?

Ultragenyx Pharmaceutical Inc. Management structure

Dr. Emil D. Kakkis, M.D.,PhD

Director, President and Chief Executive Officer

Mr. Theodore A. Huizenga

Senior Vice President, Corporate Controller and Chief Accounting Officer

Mr. Howard Horn

Chief Financial Officer and Executive Vice President, Corporate Strategy

Ultragenyx Pharmaceutical Inc. Board of directors

Dr. Deborah L. Dunsire,M.D.

Independent Director

Mr. Matthew K. Fust

Independent Director

Dr. Emil D. Kakkis, M.D.,PhD

Director, President and Chief Executive Officer

Mr. Daniel G. Welch